Home >
Sitemap
Sitemap
- Home
- About
- Products
- Investors
- ASX Announcements
- Adelaide Innovation Champion AWARDS
- Appendix 4D
- Interim Results
- Change of Address
- Appendix 4C
- Market Update
- Australian Patent Granted for Key Technology
- Appendix 4E
- First Royalty Payment Received
- bioMerieux Guest Presentation
- CEO/MD's Investor Presentation Update
- CEO/MD's Address to Shareholders
- Chairman's Address to Shareholders
- Results of AGM
- Company Name Change
- Profit Forecast
- Appendix 4C - Quarterly
- LBT Key European Patent Granted
- Appendix 4D
- Half Year Results
- LBT Achieves Next Milestone Payment
- Appendix 4C - Quarterly
- First Australian PREVI Isola Sale Made to Melbourne Pathology
- Appendix 4C - Quarterly
- Preliminary Final Report 2010 (App 4E)
- Preliminary Final Report 2010 Announcement
- Key US Patent Granted for Breakthrough LBT Lab Automation Technology
- Notice of AGM 2010 / Proxy Form
- Appendix 4C - Quarterly
- AGM 2010 Chairman's Address
- AGM 2010 Results of Meeting
- AGM 2010 CEO/MD's Address
- LBT Innovations Ltd Share Trading Policy
- Earnings Guidance
- Resignation of Non-executive Director
- Change of Director's Interest Notice
- Appendix 4C - Quarterly
- Mike Hirshorn to join LBT Board
- Appendix 4D - Half Yearly Results
- Sale of 100th Previ Isola
- Appendix 4C - Quarterly
- Earnings Guidance
- Appendix 4C - Quarterly
- Preliminary Final Report
- Details of Company Address
- Notice of Annual General Meeting/Proxy Form
- Appendix 4C - Quarterly
- Director Resignation
- Final Director's Interest Notice
- Appendix 3B
- Chairman's Address to Shareholders
- AGM 2011 CEO/MD's Address
- Results of Meeting
- Constitution
- Earnings Guidance
- Appendix 4C - Quarterly
- LBT and bioMerieux Agree Minimum Royalty
- Appendix 4D Half Yearly Results
- Director Appointment
- LBT Lodges International Patents
- Shareholder News March 2012
- Appendix 4C - Quarterly
- Appendix 4C - Quarterly
- Preliminary Final Report
- Notice of Annual General Meeting/Proxy Form
- Appendix 4C - Quarterly
- AGM 2012 Results
- AGM 2012 Director's Presentation C. Popper
- AGM 2012 CEO/MD's Address
- Chairman's Address to Shareholders
- Earnings Guidance
- Appendix 4C - Quarterly
- Appendix 4D Half Year Results
- LBT Enters Into Exclusive Discussions
- Appendix 4C - Quarterly
- Market Update on Discussions with Hettich AG Switzerland
- Options Expiry Notice
- LBT Innovations Finalises Joint Venture
- Options Expiry Notice
- Profit Guidance
- LBT Wins Grant for APAS Development
- Appendix 4C - Quarterly
- Preliminary Final Report
- 2013 Annual Report
- 2013 AGM CEO Presentation
- 2013 AGM Chairman's Address
- 2013 AGM Results
- Appendix 4D Half Year Results
- Appendix 4C -- quarterly
- LBT Innovations Introduces Landmark Diagnostic Platform
- APAS ECCMID Poster
- Investor and Shareholder Presentation
- LBT Innovations receives third $1M milestone payment
- Trading Halt
- A$1.5M LBT Private Placement and SPP
- Appendix 3B
- Placement -- Tranche 1 Cleansing Notice
- SPP Offer Documents and Notice of EGM for August 1st 2014 despatched to shareholders
- LBT Innovations Presents Results of Most Extensive Study
- Australian Society for Microbiology presentation on APAS®
- Completion of Share Purchase Plan Raising
- Appendix 4C - quarterly report
- Chairman's Address to Shareholders
- Results of EGM
- Office Relocation
- Appendix 3B
- Placement -- Cleansing Notice
- Despatch of SPP and Tranche 2 Holding Statements
- LBT Appoints US-based Clinical Trial Co-ordinator
- LBT Innovations Appoints Chief Financial Officer
- Appendix 4E
- LBT Innovations receives $3M 2014 R&D tax incentive
- LBT Begins Clinical Trials of APAS Technology
- Notice of Annual General Meeting/Proxy Form
- Annual Report to shareholders
- LBT awarded $250,000 Grant for Woundvue
- Appendix 4C -- quarterly
- Chairman's Address to Shareholders
- AGM CEO Presentation
- Results of Meeting
- Change of Company Secretary
- LBT Completes Australian Clinical Trials of APAS Technology
- CEO Presentation at Ausbiotech Biotech Invest Summit
- Notice of Intent re PREVI Isola Licence Agreement
- Appendix 4C -- quarterly report
- Appendix 4D
- LBT Granted First U.S. Patent for APAS® Technology
- Shareholder Newsletter April 2015
- Appendix 4C -- quarterly report
- LBT Begins Key U.S. Trial of APAS Technology
- Appendix 4C -- quarterly report
- LBT signs agreement with bioMerieux
- Appendix 4E
- Notice of AGM and Proxy Form
- Annual Report to Shareholders
- Appendix 4G
- LBT Announces Retirement of CEO
- LBT Receives Notice Of Allowance For Second Patent Covering Core APAS Technology In U.S.
- Appendix 4C
- AGM 2015 CEO Presentation
- AGM 2015 Chairman's Address to Shareholders
- AGM 2015 Results of Meeting
- Results of US Clinical Trial
- LBT Concludes APAS Clinical Trial Program
- LBT completes FDA submission for APAS
- Appendix 4C
- Appendix 4D
- LBT Receives Notice Of Allowance For Third Patent Related To Core APAS Technology In United States
- Appendix 4C
- Cochlear Executive Brent Barnes Appointed CEO of LBT Innovations
- LBT Granted Patent in Japan for Core APAS Technology
- Retiring LBT Innovations CEO Lusia Guthrie appointed Chair of Clever Culture Systems AG
- June Quarter 2016 Appendix 4C
- Preliminary Final Report
- Appendix 4G
- Annual Report to Shareholders
- US FDA grants approval for LBT's Automated Plate Assessment System (APAS®)
- Company Update
- September Quarter 2016 Appendix 4C
- LBT Notice of Meeting
- LBT Innovations Granted New Patent for United States
- AGM 2016 Chairman's Address to Shareholders
- AGM 2016 CEO Presentation
- Results of Annual General Meeting
- LBT Announces Completion of $7 Million Placement
- Investor Presentation
- Notice under Section 708A
- Notice of Extraordinary General Meeting
- 2017 EGM CEO Presentation
- 2017 EGM Results of Meeting
- Appendix 4C
- LBT to present at Melbourne Investor Forum
- LBT Business Update
- Appendix 4D
- Media and investor sneak peek of the first APAS® Independence demonstration device
- APAS® included on the Australian Register of Therapeutic Goods as an In Vitro Diagnostic Device
- Business Update
- APAS® Independence demonstration device ready ahead of ECCMID Conference
- Bioshares analyst review: LBT Innovations – APAS Independence Unveiled
- Appendix 4C
- Amended Annual Reports
- Share Purchase Plan Offer
- ASX LBT Newsletter Update
- SPP Cleansing Notice
- Share Purchase Plan Offer Booklet
- LBT Innovations Appoints Artificial Intelligence Expert and Entrepreneur Matthew Michalewicz to the Board
- LBT Appointed Distributor of APAS® for Australia and New Zealand
- St Vincent's Hospital in Melbourne to be global first APAS® trial site
- CE Self Certification for APAS® Independance Finalised
- LBT Innovations Conference Call with CEO and MD Brent Barnes
- LBT Investor Conference Call Business Update
- LBT Investor Conference Call Questions and Answers
- Share Purchase Plan Closes
- Appendix 4C - 10 July 2017
- Appendix 3B - 10 July 2017
- Long Serving LBT Innovations Chairman Bob Finder to Retire
- LBT's WoundVue Prototype to be used at Central Adelaide Health Network
- Corporate Governance
- Annual Reports
- Corporate Directory
- Analyst Coverage
- Brent Barnes Interview with Tom Piotrowski on the Commsec Executive Series
- Biotech Daily LBT-Apr-13-2017
- Bioshares No. 701 -- LBT Innovations
- NAB Trade -- 4 Stocks under 50 cents
- Bioshares No. 669 -- LBT Innovations
- Bioshares No. 690 -- LBT Innovations
- LBT Innovations keen on cornerstone-type investor to help develop wound product - CEO
- Under the Radar Issue 250
- CEO Interviews: LBT Innovations brings AI to pathology labs – a healthcare investment worth a (pee)k
- Former Cochlear exec’s robot microbiologist is four times faster than a human
- ASX Announcements
- Media
- Company News
- The Role of Automation in Limiting the Spread of Multi-Drug Resistant Organisms
- US FDA grants approval for LBT's Automated Plate Assessment System (APAS®)
- Company Update
- LBT Notice of Meeting
- New LBT Research Published in ASM's Journal of Clinical Microbiology
- LBT Innovations Granted New Patent For United States
- AGM 2016 CEO Presentation
- MergerMarket publishes: MicroStreak options to shift focus to APAS
- LBT Announces Completion of $7 Million Placement
- Investor Presentation
- LBT announces new Scientific Director
- LBT Business Update
- Share Purchase Plan Offer
- Clever Culture Systems Display APAS® Instruments at ECCMID 2017
- Why We Should All Be Worried About Antibiotic Resistance
- LBT Shareholder News May 2017
- Share Purchase Plan Offer Booklet
- LBT Innovations Appoints Artificial Intelligence Expert and Entrepreneur Matthew Michalewicz to the Board
- LBT Appointed Distributor of APAS® for Australia and New Zealand
- St Vincent's Hospital in Melbourne to be global first APAS® trial site
- CE Self Certification for APAS® Independance Finalised
- LBT Innovations Conference Call with CEO and MD Brent Barnes
- LBT Investor Conference Call Business Update
- LBT Investor Conference Call Questions and Answers
- Share Purchase Plan Closes
- Long Serving LBT Innovations Chairman Bob Finder to Retire
- LBT's WoundVue Prototype to be used at Central Adelaide Health Network
- LBT Innovations Receives 2017 SA Science Award for Excellence in Research Collaboration
- FAQ
- Company News
- Contact Us
- Subscribe